<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02517957</url>
  </required_header>
  <id_info>
    <org_study_id>14401970200</org_study_id>
    <nct_id>NCT02517957</nct_id>
  </id_info>
  <brief_title>Xia Shi Surgical Treatment for Eczema Multi-center Clinical Research</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Yueyang Integrated Medicine Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Yueyang Integrated Medicine Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      On the basis of Xiashi skin surgery clinical experience, this project adopts the multicenter,
      randomized, double-blind, controlled trial of design type. Objective, normative evaluation of
      traditional Chinese medicine cool blood latent town effectiveness of therapeutic regimen in
      the treatment of eczema, security, and control of the relapse of situation, provide
      high-level evidence-based basis for traditional Chinese medicine treatment of eczema, aims to
      form suitable for popularization and application of traditional Chinese medicine in the
      treatment of eczema.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the Eczema Area and Severity Index (EASI) score</measure>
    <time_frame>Baseline and up to week 4 of the follow up phase</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dermatology life quality index (DLQI)</measure>
    <time_frame>Baseline and up to week 4 of the follow up phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Itching degree score</measure>
    <time_frame>Baseline and up to week 4 of the follow up phase</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">342</enrollment>
  <condition>Eczema</condition>
  <arm_group>
    <arm_group_label>Qinzhuliangxue Keli</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Qinzhuliangxue Keli(common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.), loratadine tablets placebo (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>loratadine tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Qinzhuliangxue Keli placebo (common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.),Loratadine tablets (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Qinzhuliangxue and loratadine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Qinzhuliangxue Keli (common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.), loratadine tablets (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furoic acid loperamide hydrochloride cream</intervention_name>
    <description>Apply to lesion area without erosion, drainage, 1 times a day, continuous use 1 week after according to disease reduction or withdrawal, the longest do not exceed 4 weeks. Pure dry area or no skin itching area should not be applied.</description>
    <arm_group_label>Qinzhuliangxue Keli</arm_group_label>
    <arm_group_label>loratadine tablets</arm_group_label>
    <arm_group_label>Qinzhuliangxue and loratadine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mullite ointment</intervention_name>
    <description>Applies to a blister, pustule, erosion, ulcer, leaking or comorbid folliculitis, in skin lesions of 2 times a day, 5 days for one period of treatment, but for two consecutive period of treatment</description>
    <arm_group_label>Qinzhuliangxue Keli</arm_group_label>
    <arm_group_label>loratadine tablets</arm_group_label>
    <arm_group_label>Qinzhuliangxue and loratadine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3% boric acid solution</intervention_name>
    <description>3% boric acid solution is suitable for the erosion seepage skin, can open intermittent shi fu, 5-10 min each time, 2 times daily or several times.</description>
    <arm_group_label>Qinzhuliangxue Keli</arm_group_label>
    <arm_group_label>loratadine tablets</arm_group_label>
    <arm_group_label>Qinzhuliangxue and loratadine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zine oxide</intervention_name>
    <description>In wet apply the break to zinc oxide preparation for external use only, when erosion seepage control is disabled in skin lesions.</description>
    <arm_group_label>Qinzhuliangxue Keli</arm_group_label>
    <arm_group_label>loratadine tablets</arm_group_label>
    <arm_group_label>Qinzhuliangxue and loratadine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  accord with standard of syndrome differentiation of traditional Chinese medicine
             (blood hot sheng) and western medicine diagnostic criteria (subacute eczema);

          -  age between 18-65 years old, gender, ethnic unlimited;

          -  agreed to participate in clinical trials can observe and cooperate with the visitor on
             schedule;

          -  volunteered for this study and obtain informed consent will be;

          -  lesion area of about 5-30% of surface area (BSA) were (containing 3% and 3%, palm
             measurement method)

          -  IGA scale of 1 to 3 points (including);

          -  her lesions mainly located in the trunk and limbs (or);

          -  Women HCG negative;

        Exclusion Criteria:

          -  known to the study of drug allergy to any of the components;

          -  previous or current with any may affect the results of systemic disease, or other
             activity of skin diseases (such as: psoriasis);

          -  has a liver and kidney function is not complete, liver damage of ALT and AST &gt; 1.5
             times the upper limit of normal, renal BUN &gt; 1.5 times the upper limit of normal or
             creatinine &gt; 1.5 times the upper limit of normal value;

          -  QTcB or QTcF acuity 450 milliseconds. For subjects QTc acuity bundle branch block 480
             milliseconds.

          -  prior or current with clinical significance of cardiovascular, lung disease,
             gastrointestinal tract, liver, kidney, blood, nerve abnormalities or mental disease;

          -  breast-feeding or plan to pregnant women during test;

          -  skin area score &gt; 30%;

          -  eosinophil count score &gt; 10%

          -  for nearly two weeks taking corticosteroids or a week, both inside and outside with
             corticosteroid preparation;

          -  three months received study medication or other participated in other clinical
             subjects;

          -  for any reason cannot cooperate research, for example: how language understanding, not
             to research centers, etc.;

          -  Researchers believe can bring obvious risk patients or confuse the results of the
             study, which should rule out other conditions or disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Li Bin, director</last_name>
    <phone>0086-021-65162629</phone>
    <email>18930568129@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Fulun, researcher</last_name>
    <phone>0086-021-65162629</phone>
    <email>drlifulun@163.com</email>
  </overall_contact_backup>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2015</study_first_submitted>
  <study_first_submitted_qc>August 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2015</study_first_posted>
  <last_update_submitted>August 6, 2015</last_update_submitted>
  <last_update_submitted_qc>August 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Xiashi surgical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loratadine</mesh_term>
    <mesh_term>Loperamide</mesh_term>
    <mesh_term>Antidiarrheals</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

